Analysts think ALT stock price could increase by 224%
Dec 26, 2024, 12:26 PM
-7.55%
What does ALT do
Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
6 analysts think ALT stock price will increase by 224.24%. The current median analyst target is $24.48 compared to a current stock price of $7.55. The lowest analysts target is $12.12 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
